Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1

Anne Sophie Grosch 1 • Jan Leo Rinnenthal 2,3,4 • Maria Rönnefarth 1,5 • Silke Lux 6 • Michael Scheel 4,7 • Matthias Endres 1,4,8,9,10 • Alexander U. Brandt 4,11 • Friedemann Paul 1,3,4 • Tanja Schmitz-Hübsch 1,4 • Martina Minnerop 12,13 • Sarah Doss 1,14

Accepted: 4 October 2020 / Published online: 15 October 2020 © The Author(s) 2020

Abstract
Autosomal-dominant spinocerebellar ataxias (SCA) are neurodegenerative diseases characterized by progressive ataxia. Here, we report on neurometabolic alterations in spinocerebellar ataxia type 1 (SCA1; SCA-ATXN1) and 14 (SCA14; SCA-PRKCG) assessed by non-invasive 1H magnetic resonance spectroscopy. Three Tesla 1H magnetic resonance spectroscopy was performed in 17 SCA14, 14 SCA1 patients, and in 31 healthy volunteers. We assessed metabolites in the cerebellar vermis, right cerebellar hemisphere, pons, prefrontal, and motor cortex. Additionally, clinical characteristics were obtained for each patient to correlate them with metabolites. In SCA14, metabolic changes were restricted to the cerebellar vermis compared with widespread neurochemical alterations in SCA1. In SCA14, total N-acetylaspartate (tNAA) was reduced in the vermis by 34%. In SCA1, tNAA was reduced in the vermis (24%), cerebellar hemisphere (26%), and pons (25%). SCA14 patients showed 24% lower glutamate+glutamine (Glx) and 46% lower γ-aminobutyric acid (GABA) in the vermis, while SCA1 patients showed no alterations in Glx and GABA. SCA1 revealed a decrease of aspartate (Asp) in the vermis (62%) and an elevation in the prefrontal cortex (130%) as well as an elevation of myo-inositol (Ins) in the cerebellar hemisphere (51%) and pons (46%). No changes of Asp and Ins were detected in SCA14. Beyond, glucose (Glc) was increased in the vermis of both SCA14 (155%) and SCA1 (247%). 1H magnetic resonance spectroscopy revealed differing neurochemical profiles in SCA1 and SCA14 and confirmed metabolic changes that may be indicative for neuronal loss and dysfunctional energy metabolism. Therefore, 1H magnetic resonance spectroscopy represents a helpful tool for in-vivo tracking of disease-specific pathophysiology.

Keywords Spinocerebellar ataxia • 1H magnetic resonance spectroscopy • SCA1 • SCA14 • Neurochemical profile

Introduction
Spinocerebellar ataxias (SCA) are a group of autosomal-dominant disorders that present as progressive cerebellar ataxia. They have a prevalence of up to 5.6 patients out of 100,000 individuals [1] however with a suspected large number of genetically unconfirmed cases. Depending on the genotype, these disorders lead to atrophy patterns that include the cerebellum and variable regions in the brainstem, basal ganglia, and cerebral cortex. Hence, patients share a cerebellar syndrome but show different concomitant symptoms. The cerebellar involvement and especially the extra-cerebellar degeneration display SCA subtype-specific patterns [2, 3]. The most prevalent SCA subtypes, among them SCA1, are caused by trinucleotide repeat expansion mutations, and the majority presents widespread central nervous system (CNS) involvement [4]. Many among the more recently identified SCA subtypes caused by missense and deletion mutations, such as SCA14, display a cerebellar syndrome with scarce extracerebellar manifestations. Neuroimaging studies in SCA14 are confined to case series, and specific atrophy patterns are not well described. SCA14 is caused by missense or deletion mutations in the protein kinase C gamma gene (PRKCG), which is mainly attributed to signal transduction, cell proliferation, and synaptic transmission in Purkinje cells [4]. SCA14 patients suffer from a slowly progressive ataxia. Other symptoms like cognitive impairment, mild sensory impairment,
Some patients had previously participated in different MRI confirmed pathogenic expansion in ATXN1 were included. Variants in PRKCG as well as fourteen SCA1 patients with controls (HC). Seventeen SCA14 patients with pathogenic expression were recruited to match each patient to a healthy volunteer of equal gender and similar age (± 3 years). Inclusion criteria for patients were minimum age of 18 years and genetically confirmed diagnosis of SCA14 or SCA1. Exclusion criteria were contraindication for the use of MRI, lack of ability to communicate, and diseases of the CNS other than SCA. Inclusion criterion for healthy controls was minimum age of 18 years, and exclusion criteria were contraindications for the use of MRI as well as neurologic diseases or neurological treatment in the medical background. For all patients, scale for the assessment and rating of ataxia (SARA), score of the cognitive screening test for mild cognitive impairment and early dementia (DemTect), age of onset, and disease duration were obtained. The score of SARA ranges from 0 to 40 with 0 referring to no ataxia and 40 referring to most severe ataxia [14]. If circumstances permitted, SARA was assessed immediately before or after brain scanning. The score of DemTect ranges from 0 to 18 points with 13–18 points corresponding to cognitive power appropriate for age, 9–12 points corresponding to mild cognitive impairment, and 0–8 points corresponding to suspected dementia [15].

1H Magnetic Resonance Spectroscopy

Single-voxel 1H magnetic resonance spectroscopy was performed using a 3 T scanner (Siemens Magnetom Trio, Erlangen) at the Charité Berlin Center of Advanced Imaging (BCAN). A point resolved spectroscopy sequence (PRESS) was established for stimulation pulses, and the chemical shift selective (CHESS) technique with bandwidth set to 20 Hz was applied in order to suppress the water signal. An TE of 30 ms, which allows assessing metabolites with short relaxation times and a repetition time of 3000 ms were used. In addition to 1H magnetic resonance spectroscopy sequences, magnetization-prepared rapid gradient echo (MPRAGE) and sampling perfection with application-optimized contrasts using different flip angle evolution (T2 3D SPACE) sequences were conducted to control for pathologies different from cerebellar atrophy. The standard birdcage one-channel head coil was used for spectroscopy and a 12-channel head coil for MPRAGE and T2 3D SPACE. Sagittal, coronal, and transversal T2-weighted turbo spin-echo MR sequences were used for positioning the VOI. The VOI were positioned in each individual’s brain manually in the vermis, right cerebellar hemisphere, pons, prefrontal cortex, and motor cortex as illustrated in Fig. 1. The VOI in the cerebellar hemisphere included the dentate nucleus, which experiences distinct neuronal loss and atrophy in SCA1 [16, 17] and was positioned right cerebellar in accordance with our previous studies [9, 10]. The VOI localized in extra-cerebellar brain regions were intentionally positioned in the midline in order to maximize the partial volume of cortical tremor, or axial myoclonus have been reported [5]. SCA1 is caused by a CAG-repeat expansion in the gene ataxin-1 (ATXN1) on chromosome 6p23 [6]. This gene encodes for the protein ataxin-1, which is suggested to regulate gene expression [7]. Besides progressive ataxia, the phenotype includes supranuclear opthalmoplegia, pyramidal signs, peripheral neuropathy [5], or retinal nerve degeneration [8].

This study was designed based on our previous studies in SCA14 [9] and SCA1 [10]. Compared with these previous total n-acetylaspartate (tNAA) focused studies, we optimized our spectroscopic methods, used a shorter echo time (TE), included more metabolites into the analysis, examined extended patient cohorts of both SCA1 and SCA14, and introduced two cerebellar volumes of interest (VOI) and an extracerebellar VOI in the brainstem. In the present study, we aimed to assess metabolic changes in SCA14 and SCA1 patients in both cerebellar and extra-cerebellar regions in order to differentiate them from a control group as well as to identify differences and similarities of these subtypes based on their metabolic profile. An extensive neurochemical profiling might be able to reveal subtype-specific and/or cross-subgroup biomarkers that could be used for facilitation of diagnostic procedures and demonstration of starting points for future therapeutics. Since SCA1 is characterized by widespread neuronal loss and brainstem atrophy [4], we hypothesized that metabolic alterations will be present in the pons. In contrast, we hypothesized that metabolic alterations in SCA14 will be limited to the vermis and cerebellar hemisphere due to the localization of Purkinje cells and expression of protein kinase C gamma. Moreover, we correlated clinical examination scores and characteristics with in vivo levels of each metabolite to check for associations with prognostic significance on the clinical course. For the assessment of brain metabolites, we considered 1H magnetic resonance spectroscopy as a powerful tool to analyze the human brain metabolism in vivo. This technique allows for non-invasive detection of biochemical alterations and quantification of metabolites in symptomatic [11] and presymptomatic SCA patients [12]. In addition, 1H magnetic resonance spectroscopy is able to distinguish between SCA subtypes [11], and the results of different medical centers are reproducible if identical spectroscopy settings are applied [13].

Methods

Participants

We conducted a cross-sectional study with matched healthy controls (HC). Seventeen SCA14 patients with pathogenic variants in PRKCG as well as fourteen SCA1 patients with confirmed pathogenic expansion in ATXN1 were included. Some patients had previously participated in different MRI

1H magnetic resonance spectroscopy studies at our center, published elsewhere [9, 10]. Thirty-one healthy controls were recruited to match each patient to a healthy volunteer of equal gender and similar age (± 3 years). Inclusion criteria for patients were minimum age of 18 years and genetically confirmed diagnosis of SCA14 or SCA1. Exclusion criteria were contraindication for the use of MRI, lack of ability to communicate, and diseases of the CNS other than SCA. Inclusion criterion for healthy controls was minimum age of 18 years, and exclusion criteria were contraindications for the use of MRI as well as neurologic diseases or neurological treatment in the medical background. For all patients, scale for the assessment and rating of ataxia (SARA), score of the cognitive screening test for mild cognitive impairment and early dementia (DemTect), age of onset, and disease duration were obtained. The score of SARA ranges from 0 to 40 with 0 referring to no ataxia and 40 referring to most severe ataxia [14]. If circumstances permitted, SARA was assessed immediately before or after brain scanning. The score of DemTect ranges from 0 to 18 points with 13–18 points corresponding to cognitive power appropriate for age, 9–12 points corresponding to mild cognitive impairment, and 0–8 points corresponding to suspected dementia [15].
brain tissue as well as to have both hemispheres represented within the VOI. We decided against investigating additional VOI in order to not further extend the total scanning time of approximately 1 h. Each VOI measured 20 × 15 × 15 mm³ in the cerebellar locations and pons in contrast to 20 × 20 × 20 mm³ in the cerebrocortical regions. We intentionally decided not to correct for cerebrospinal fluid in order to avoid additional errors that come along due to error propagation. No morphologically self-evident variations in partial volume effects were seen during planning the VOI.

We quantified the following metabolites: alanine (Ala), aspartate (Asp), creatine (Cr), phosphocreatine (PCr), γ-aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glycerophosphocholine (GPC), phosphocholine (PCh), glutathione (GSH), myo-inositol (Ins), lactate (Lac), n-acetylaspartate (NAA), n-acetylaspartylglutamate (NAAG), scyllo-inositol (Scyllo), taurine (Tau), negative creatine methylene (CrCH2), total choline (tCho), total n-acetylaspartate (tNAA), total creatine (tCr), and Glu+Gln (Glx). The investigated metabolites are expressed in arbitrary units (AU), because an exact calibration is not achievable. They serve as markers for neuronal density and viability (NAA, NAAG, tNAA), energy metabolism (Glc, Lac, Cr, PCr, tCr), neurotransmission (GABA, Glu, Gln, Glx), glial marker (Ins, Scyllo), membrane turnover and cellularity (GPC, PCh, tCho), antioxidant system (GSH), and amino acids (Ala, Asp, Tau) [18]. CrCH2 represents a correction term. An exemplaric spectrum is given in Fig. 2.

**Statistical Analysis**

Quantification of metabolites (Fit) was realized with the LCModel software package (Version 6.3-1L) with a current PRESS basis set for 3 T and TE = 30 ms (delivered by Stephen W. Provencher). As base system, Debian GNU/Linux (version 5.0.10) was used. Mostly, data were not normally distributed as proven by visual impression and Shapiro-Wilk test. As a consequence, Kruskal-Wallis test with adjusted p values according to Bonferroni correction was used for group comparisons of metabolites between the three groups of SCA14, SCA1, and HC. Metabolite changes are presented as percentages. For group comparisons of demographic and clinical data, the chi-square test (for female sex), Kruskal-Wallis test (for age at examination), and Mann-Whitney U test (for age of onset, disease duration, SARA, and DemTect) were applied. Linear relationships between metabolite levels, and clinical features were evaluated using linear regression analysis with adjustment for age as a major confounding factor. For this analysis, SCA14 and SCA1 cohorts had to be merged due to the small sample size of both patient groups. Statistical
analyses and charts were performed using IBM SPSS (www.ibm.com, version 24). A \( p \) value \( \leq 0.05 \) was considered as significant. Missing data points, but no complete data sets, were excluded from analyses. In order to ensure sufficient measurement accuracy, individual measurements were excluded from the study if spectral bandwidth exceeded 0.125 ppm, signal-to-noise ratio was bad, or significant artifacts were present. Resulting group sizes are given in the text and Fig. 3.

Results

Study Population

Groups did not differ in terms of sex, age at examination, age of onset, SARA, and DemTect. However, SCA14 patients revealed a significant longer mean disease duration compared with SCA1 patients (see Table 1). The same was true for the smaller subsamples of HC, SCA14, and SCA1 after elimination of spectra with insufficient quality: SCA14 patients demonstrated significant longer mean disease durations in each VOI compared with SCA1 patients, while the remaining demographic and clinical data were balanced between the groups. The metabolites Glu, Ins, tCho, tNAA, tCr, and Glx revealed an average Cramer-Rao lower bound (CRLB) of \( \leq 20\% \), allowing for a robust and valid interpretation.

Fig. 2 Exemplaric spectrum of the prefrontal cortex from a healthy control included in this study. Total creatine (tCr) results from two spectral peaks (Cr and PCr). Abbreviations: tCr, total creatine; Ins, myo-inositol; tCho, total choline; Glx, glutamate+glutamine; tNAA, total n-acetylaspartate (NAA+NAAG); MM, macromolecules

Fig. 3 Neurochemical profiles illustrating averaged metabolites of control group, SCA14, and SCA1 for each of the five VOI vermis, cerebellar hemisphere, pons, prefrontal cortex, and motor cortex. Standard deviations are represented as error bars. Significance is marked with * \( (p \leq 0.05) \), ** \( (p \leq 0.01) \), or *** \( (p \leq 0.001) \) asterisks. Abbreviations: HC, healthy controls; AU, arbitrary units; Ala, alanine; Asp, aspartate; Cr, creatine; PCr, phosphocreatine; GABA, \( \gamma \)-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; GPC, glycerophosphorylcholine; PCh, phosphocholine; GSH, glutathione; Ins, myo-inositol; Lac, lactate; NAA, n-acetylaspartate; NAAG, n-acetylaspartylglutamate; Scylo, scyllo-inositol; Tau, taurine; CrCH2, negative creatine methylene (correction term); tCho, total choline; tNAA, total n-acetylaspartate (NAA+NAAG); tCr, total creatine; Glx, glutamate+glutamine
Neurochemical Alterations in SCA14

Changes in the neurochemical profile of SCA14 patients revealed no involvement of cerebellar hemisphere or extracerebellar structures (pons, prefrontal cortex, or motor cortex). The vermis was the only brain area that showed extensive metabolic changes. Metabolic changes of the vermis (n = 13) demonstrated a reduction of tNAA by 34% (p < 0.001) and NAA by 40% (p < 0.001). Although differentiation between NAA and NAAG is difficult using 1H magnetic resonance spectroscopy, we detected no changes in NAAG. Besides, we report about markers associated with energy metabolism alterations. SCA14 patients showed a reduction in tCr by 22% (p = 0.001), Glu by 32% (p < 0.001), Glx by 24% (p < 0.001), and GABA by 46% (p = 0.003) in the vermis. There was no change of Gln in the vermis. However, differentiation of Glu and Gln is difficult, and reliability is limited using 3 T 1H magnetic resonance spectroscopy. Consistent with energy metabolism changes, we identified an elevation of GPC by 155% (p = 0.026) in the vermis. Furthermore, tCho was reduced by 20% (p = 0.001) in the vermis. In contrast to SCA1 spectra, no significant alterations were identified for Asp and Ins in SCA14.

Neurochemical Alterations in SCA1

In SCA1, we identified extended metabolic changes detectable in each VOI with a focus on vermis, cerebellar hemisphere, and pons. We analyzed n = 12 patients in the vermis, n = 10 in the cerebellar hemisphere, n = 9 in the pons, n = 10 in the prefrontal cortex, and n = 12 in the motor cortex after exclusion of spectra with insufficient quality. Here, we detected a tNAA reduction by 24% in the vermis (p < 0.001), by 26% in the cerebellar hemisphere (p = 0.001), and by 25% in the pons (p = 0.017), but not in the prefrontal or motor cortices. NAA was decreased by 28% in vermis (p = 0.002), by 22% in the cerebellar hemisphere (p = 0.007), and by 16% in the motor cortex (p = 0.015). In addition, our SCA1 patient cohort revealed an elevation of Ins by 51% in the cerebellar hemisphere (p = 0.007) and by 46% in the pons (p = 0.005). No changes in Ins were detectable in the vermis. The energy metabolism showed an elevation of tCr by 18% in the cerebellar hemisphere (p = 0.028) as well as an elevation of Glc by 247% in the vermis (p < 0.001). Moreover, the vermis of SCA1 patients presented with a reduction of tCho by 15% (p = 0.007) and a tendency for Glu reduction by 15% (p = 0.086). Besides, we identified an Asp reduction by 62% in the vermis (p = 0.019) and a marked elevation by 130% in the prefrontal cortex (p = 0.025). In the motor cortex, Scyllo was reduced by 90% in SCA1 patients (p = 0.003). In contrast to SCA14 spectra, none of the investigated brain areas revealed significant changes in GABA or Glx levels in SCA1.

Neurochemical Differences Between SCA14 and SCA1

In the vermis, SCA14 patients revealed 21% lower tCr in comparison with SCA1 patients (p = 0.025). Compared with SCA14, SCA1 patients showed an elevation of Ins by 37% in the vermis (p = 0.015) and by 59% in the cerebellar hemisphere (p = 0.007). In the cerebellar hemisphere, 67% higher GSH (p = 0.038) and a trend for 17% lower Glu (p = 0.051) were detectable in SCA1 compared with SCA14. In addition, SCA1 patients demonstrated a tNAA reduction by 22% in the cerebellar hemisphere (p = 0.046) and by 28% in the pons (p = 0.014) in relation to SCA14 patients. There were no metabolic differences in the prefrontal cortex. In the motor cortex, SCA1 patients presented with 88% lower Scyllo (p = 0.039) and a tendency for 90% lower Tau (p = 0.055) compared with SCA14 patients.

Regression Analysis with Adjustment for Age

SARA

In the cerebellar hemisphere and pons, bad motor performance (high SARA scores) were linked to low NAA (p = 0.048; p =

---

Table 1 Demographic data and clinical characteristics of study participants

|                            | HC (n = 31) | SCA14 (n = 17) | SCA1 (n = 14) | P value |
|---------------------------|------------|---------------|---------------|---------|
| Female sex, n (%)         | 16 (51.6%) | 9 (52.9%)     | 7 (50.0%)     | 0.987   |
| Age at examination in years, mean (SD) | 48.1 (13.1) | 50.9 (12.8) | 44.8 (12.4) | 0.363   |
| SARA score, mean (SD)     | 11.0 (3.6) | 13.5 (6.9)    | 12.0 (3.5)    | 0.263   |
| DemTect score, mean (SD)  | 14.5 (3.6) | 12.0 (3.5)    | 13.5 (6.9)    | 0.246   |
| Age of onset in years, mean (SD) | 31.2 (14.8) | 36.7 (12.5) | 37.4 (13.5) | 0.325   |
| Disease duration in years, mean (SD) | 19.6 (2.9) | 7.8 (4.7)    | 12.0 (3.5)    | 0.004a  |

HC healthy controls, SCA14 spinocerebellar ataxia type 14, SCA1 spinocerebellar ataxia type 1, n quantity, SD standard deviation, SARA scale for the assessment and rating of ataxia, DemTect cognitive screening test for mild cognitive impairment and early dementia, a significant group difference in disease duration between SCA14 and SCA1.
3-T single-voxel 1H magnetic resonance spectroscopy. In this study we assessed metabolic changes in cerebellar and extra-cerebellar brain regions. In SCA14 metabolic changes were strongly restricted to the vermis, whereas the cerebellar hemisphere was included. In SCA1 patients, more widespread metabolic changes were present. The tNAA reduction was not only found in the vermis of SCA1 patients but also in the cerebellar hemisphere, pons, and as a trend in the motor cortex. Furthermore, the SCA1 cohort featured an Ins elevation in the cerebellar hemisphere, which was more pronounced in the SCA1 than in the SCA14 cohort (247% vs. 155%). Supporting these results, Glc levels were elevated in the cerebellum of mice overexpressing mutant human ataxin-1 [21]. Also, SCA1 patients revealed an increase of Glc+ tau amounts in the vermis [12] and cerebellar hemisphere [12, 22]. In positron emission tomography, a reduced Glc metabolism was seen in the cerebellum and brainstem of SCA1 patients [23]. In fact, a Glc hypometabolism has also been reported for other polyglutamine diseases such as SCA2, SCA3, SCA6 [24], and Huntington’s disease [25] as well as for neurodegenerative diseases without trinucleotide repeats such as Alzheimer’s disease [26], amyotrophic lateral sclerosis [27], and Parkinson’s disease [28]. Accordingly, the Glc elevation in the vermis could represent an accumulation due to a reduced Glc metabolism. In distinction from SCA14, Asp was reduced, and tCr was not changed in the vermis of SCA1 patients. Interestingly, aspartate-glutamate homeostasis in neuronal cells is affected by the availability of glucose and ketone bodies. In the presence of ketone bodies only, neurons showed higher aspartate and lower glutamate levels compared with presence of glucose alone [29]. Thus, high levels of Glc may affect aspartate levels in the vermis. However, Asp also serves as substrate for NAA synthesis, and low Asp could simply be linked to low NAA levels [30]. Since the SCA1 cohort was characterized by distinct changes in Glc and Asp as opposed to SCA14, despite a significant shorter disease duration, these metabolites might point to metabolic pathways differing between SCA14 and SCA1.

In SCA14, metabolic changes were strongly restricted to the vermis, while extra-cerebellar brain regions and particularly the cerebellar hemisphere were not involved in neurochemical alterations. In the vermis of SCA14 patients, tNAA, tCho, tCr, GABA, and Glu were mainly decreased as well as Glc was increased. The tCho reduction and Glc elevation have not been described for SCA14 yet, while the reductions in tNAA, tCr, GABA, and Glu confirm previous research [9]. The tNAA reduction is characteristic for neurodegenerative diseases and corresponds to neuronal cell loss or neuronal dysfunction [18]. Low tCr may indicate suppressed energy metabolism with a consecutive accumulation of Glc and low membrane turnover as illustrated by tCho reduction. The decreased neurotransmitters GABA and Glu may reflect loss of GABAergic Purkinje cells and loss of climbing fibers, whose effecences maintain glutamatergic synapses with Purkinje cells.

SCA1 patients demonstrated similar results in vermis: There was a significant reduction in tNAA and tCho but less pronounced than in SCA14. Although results on tCho levels in SCA1 are heterogeneous, the observed tCho reduction of the present study supports previous indications for low tCho in the cerebellum [19, 20]. Unlike SCA14, Glu was reduced in the vermis, but did not reach statistical significance in SCA1 likely due to significant longer disease duration of the SCA14 cohort. Furthermore, both subtypes had a Glc elevation in common, which was more pronounced in the SCA1 than in the SCA14 cohort (247% vs. 155%). Supporting these results, Glc levels were elevated in the cerebellum of mice overexpressing mutant human ataxin-1 [21]. Also, SCA1 patients revealed an increase of Glc+tau amounts in the vermis [12] and cerebellar hemisphere [12, 22]. In positron emission tomography, a reduced Glc metabolism was seen in the cerebellum and brainstem of SCA1 patients [23]. In fact, a Glc hypometabolism has also been reported for other polyglutamine diseases such as SCA2, SCA3, SCA6 [24], and Huntington’s disease [25] as well as for neurodegenerative diseases without trinucleotide repeats such as Alzheimer’s disease [26], amyotrophic lateral sclerosis [27], and Parkinson’s disease [28]. Accordingly, the Glc elevation in the vermis could represent an accumulation due to a reduced Glc metabolism. In distinction from SCA14, Asp was reduced, and tCr was not changed in the vermis of SCA1 patients. Interestingly, aspartate-glutamate homeostasis in neuronal cells is affected by the availability of glucose and ketone bodies. In the presence of ketone bodies only, neurons showed higher aspartate and lower glutamate levels compared with presence of glucose alone [29]. Thus, high levels of Glc may affect aspartate levels in the vermis. However, Asp also serves as substrate for NAA synthesis, and low Asp could simply be linked to low NAA levels [30]. Since the SCA1 cohort was characterized by distinct changes in Glc and Asp as opposed to SCA14, despite a significant shorter disease duration, these metabolites might point to metabolic pathways differing between SCA14 and SCA1.

In SCA14, metabolic changes were strongly restricted to the vermis, while extra-cerebellar brain regions and particularly the cerebellar hemisphere were not involved in neurochemical alterations. In the vermis of SCA14 patients, tNAA, tCho, tCr, GABA, and Glu were mainly decreased as well as Glc was increased. The tCho reduction and Glc elevation have not been described for SCA14 yet, while the reductions in tNAA, tCr, GABA, and Glu confirm previous research [9]. The tNAA reduction is characteristic for neurodegenerative diseases and corresponds to neuronal cell loss or neuronal dysfunction [18]. Low tCr may indicate suppressed energy metabolism with a consecutive accumulation of Glc and low membrane turnover as illustrated by tCho reduction. The decreased neurotransmitters GABA and Glu may reflect loss of GABAergic Purkinje cells and loss of climbing fibers, whose effecences maintain glutamatergic synapses with Purkinje cells.

SCA1 patients demonstrated similar results in vermis: There was a significant reduction in tNAA and tCho but less pronounced than in SCA14. Although results on tCho levels in SCA1 are heterogeneous, the observed tCho reduction of the present study supports previous indications for low tCho in the cerebellum [19, 20]. Unlike SCA14, Glu was reduced in the vermis, but did not reach statistical significance in SCA1 likely due to significant longer disease duration of the SCA14 cohort. Furthermore, both subtypes had a Glc elevation in common, which was more pronounced in the SCA1 than in the SCA14 cohort (247% vs. 155%). Supporting these results, Glc levels were elevated in the cerebellum of mice overexpressing mutant human ataxin-1 [21]. Also, SCA1 patients revealed an increase of Glc+tau amounts in the vermis [12] and cerebellar hemisphere [12, 22]. In positron emission tomography, a reduced Glc metabolism was seen in the cerebellum and brainstem of SCA1 patients [23]. In fact, a Glc hypometabolism has also been reported for other polyglutamine diseases such as SCA2, SCA3, SCA6 [24], and Huntington’s disease [25] as well as for neurodegenerative diseases without trinucleotide repeats such as Alzheimer’s disease [26], amyotrophic lateral sclerosis [27], and Parkinson’s disease [28]. Accordingly, the Glc elevation in the vermis could represent an accumulation due to a reduced Glc metabolism. In distinction from SCA14, Asp was reduced, and tCr was not changed in the vermis of SCA1 patients. Interestingly, aspartate-glutamate homeostasis in neuronal cells is affected by the availability of glucose and ketone bodies. In the presence of ketone bodies only, neurons showed higher aspartate and lower glutamate levels compared with presence of glucose alone [29]. Thus, high levels of Glc may affect aspartate levels in the vermis. However, Asp also serves as substrate for NAA synthesis, and low Asp could simply be linked to low NAA levels [30]. Since the SCA1 cohort was characterized by distinct changes in Glc and Asp as opposed to SCA14, despite a significant shorter disease duration, these metabolites might point to metabolic pathways differing between SCA14 and SCA1.
reduced expression of the Glu-Asp transporter (GLAST) that correlated with the loss of Purkinje neurons [31]. Moreover, Asp showed a reduction not only in the vermis of SCA1 patients but also in the pons, which did not reach statistical significance probably due to the small sample size in pons (n = 9). The pons is anatomically located in an area, where shimming in the majority of cases does not result in sufficient B0 field homogeneity and subsequently only a small number of data sets met sufficient spectral quality. Interestingly, each metabolite of tNAA, Ins, and Asp was altered to the same extent across the affected brain areas in the metencephalon (tNAA in the vermis − 24%, cerebellar hemisphere − 26%, and pons − 25%; Ins in the cerebellar hemisphere + 51% and pons + 46%; Asp in the vermis − 62% and pons − 68%). However, no changes were identified for Glu, Glc, and tCho in SCA1 outside the vermis. In contrast to the reduction of tCr in the vermis of SCA14 patients, but in line with previous research [22], we found a tCr elevation selectively in the cerebellar hemisphere of SCA1 patients. Adanyeguh and colleagues reported about tCr increases in the vermis and pons of SCA1 without investigating the cerebellar hemisphere [32]. Since tCr levels are related to mental activity [33], the discrepancy in the distribution of tCr elevations might be attributed to recently varying activity states. tCr is considered a marker for energy metabolism and serves as buffer for adenosine triphosphate (ATP) [30]. Besides a Glc hypometabolism in the cerebellum of SCA1 patients, downregulation of certain enzymes involved in glycolysis and ATP synthesis, lower ATP levels [34], and reduced activities of the respiratory chain complexes [35] were identified in the cerebellum of SCA1 mouse models. Therefore, high tCr could be a reaction on suppressed energy metabolism in order to maintain fast energy supply in case of high energy demand. Moreover, Scyllo was reduced in the motor cortex of SCA1 patients, which should be reevaluated in future studies.

Neurochemical changes were observed in SCA14 selectively in the vermis and in SCA1 throughout the cerebellum and pons. Besides changes related to the different atrophy patterns, both subtypes differed by direct comparison in the metabolites tCr, Ins, and GSH in the cerebellum as well as Scyllo and Tau in the motor cortex. Since GSH and Tau were unchanged in both patient groups compared with the control group, these results seem questionable.

Regression analysis did not reveal any significant associations between clinical data and metabolite levels in the vermis. This could be explained by focal atrophy with distinct loss of cerebellar tissue and consequently very low metabolite levels. Of note, the provided analysis tested only for linear relationships. In the cerebellar hemisphere as well as in the pons, low tNAA levels were associated with worse cognitive power (lower DemTect scores) and, in accordance with a previous study [22], worse motor performances (higher SARA scores). Although no alterations in tCho were found outside the vermis, low tCho in the cerebellar hemisphere and/or pons were indicative for poorer clinical presentation (worse SARA, worse DemTect, lower age of onset, longer disease duration). Moreover, weak associations between high Ins level in the cerebellar hemisphere and higher age of onset, respectively, shorter disease duration were identified. Since SCA14 did not reveal alterations in Ins, these associations seem to be an effect of the SCA1 cohort. Glc showed only isolated associations with clinical parameters, which were merely present in brain areas without altered Glc levels. Further investigations on Ins, tCho, and Glc levels in SCA1 and SCA14 patients are needed to confirm these results. With regard to Deelchand and colleagues [13], a multi-center study could overcome the issue of underpowered patient cohorts and clearly enhance the quality of analysis. Future studies using 1H magnetic resonance spectroscopy would also benefit from a two-staged data collection for evaluation of metabolite fluctuations/courses over time, a combination of spectroscopic with structural MRI measurements, and an inclusion of presymptomatic mutation carriers in addition to symptomatic patients.

The various SCA genotypes share cerebellar ataxia as a joint clinical characteristic and cerebellar atrophy of yet different degree and pattern. Beyond, SCA patients may share disease features common with other neurodegenerative diseases, especially mitochondrial disorders. Against this background, it seems possible that different SCA genotypes share pathological mechanisms and pathways. It remains to be shown, if SCAs with similar atrophy patterns share more pathophysiological pathways than SCAs with different patterns. Our study examined two SCA subtypes with different atrophy patterns. Still, we found common metabolic changes that are in line with previous results and might be attributed to dysfunctional energy metabolism in both SCA14 and SCA1. Since mitochondrial and glycolytic pathways have great impact on neuronal energy metabolism, these findings offer an eligible approach for further investigations in SCA14 and SCA1.

Acknowledgments We thank Susan Pikol and Cynthia Kraut for the excellent technical support. Likewise, we thank the Charité Institute of Biometry and Clinical Epidemiology for the distinguished statistical consultation. Moreover, we owe a great debt of gratitude to all patients and healthy volunteers, who participated in this study.

Authors’ Contribution Conceptualization: Sarah Doss and Jan Leo Rinnenthal.
Methodology: Sarah Doss, Jan Leo Rinnenthal, Anne Sophie Grosch, Maria Rönnefarth, Martina Minnerop, Tanja Schmitz-Hübsch, Silke Lux, and Alexander U. Brandt.
Formal analysis and investigation: Anne Sophie Grosch, Jan Leo Rinnenthal, and Michael Scheel.
Writing—original draft preparation: Anne Sophie Grosch.
Writing—review and editing: Anne Sophie Grosch, Jan Leo Rinnenthal, Maria Rönnefarth, Silke Lux, Michael Scheel, Matthias Endres, Alexander U. Brandt, Friedemann Paul, Tanja Schmitz-Hübsch, Martina Minnerop, and Sarah Doss.
Funding acquisition: Sarah Doss and Friedemann Paul.
Supervision: Friedemann Paul.
**Funding** Open Access funding enabled and organized by Projekt DEAL. This study was funded by the Ataxia UK as well as cofunded by the German Hereditary Ataxia Foundation (DHAG) and Stiftung Hoffnung.

**Data Availability** The data set analyzed in this study is available from the corresponding author on a reasonable request.

**Compliance with Ethical Standards**

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Ethics Approval** The study was approved by the local ethics committee of the Charité Universitätsmedizin Berlin and the University of Bonn and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Consent to Participate** Informed consent was obtained from all individual participants included in the study.

**Consent for Publication** Not applicable.

**Code Access** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42:174–83.

2. Hernandez-Castillo CR, King M, Diedrichsen J, Fernandez-Ruiz J. Unique degeneration signatures in the cerebellar cortex for spinocerebellar ataxias 2, 3, and 7. Neuroimage Clin. 2018;20:931–8.

3. Reetz K, Costa AS, Mirazadeh S, Lehmann A, Juzek A, Rakowicz M, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical scale in SCAs 1, 3 and 6. Brain. 2013;136:905–17.

4. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.

5. Sun YM, Lu C, Wu ZY. Spinocerebellar ataxia: relationship between phenotype and genotype - a review. Clin Genet. 2016;90:305–14.

6. Matilla-Duenas A, Gooldt R, Giunti P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum. 2008;7:106–14.

7. Yue S, Serra HG, Zoghbi HY, Orr HT. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001;10:25–30.

8. Stricker S, Oberwahrenbrock T, Zimmermann H, Schroeter J, Endres M, Brandt AU, et al. Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One. 2011;6:e23024.

9. Doss S, Rinnenthal JL, Schmitz-Hubsch T, Brandt AU, Papazoglou S, Lux S, et al. Cerebellar neurochemical alterations in spinocerebellar ataxia type 14 appear to include glutathione deficiency. J Neurol. 2015;262:1927–35.

10. Doss S, Brandt AU, Oberwahrenbrock T, Endres M, Paul F, Rinnenthal JL. Metabolic evidence for cerebral neurodegeneration in spinocerebellar ataxia type 1. Cerebellum. 2014;13:199–206.

11. Krahe J, Binkofski F, Schulz JB, Reetz K, Romanzetti S. Neurochemical profiles in hereditary ataxias: a meta-analysis of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2020;108:854–65.

12. Joens JM, Deelchand DK, Lyu T, Emir UE, Hutter D, Gomez C, et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol. 2018;83:816–29.

13. Deelchand DK, Adanyeguh IM, Emir UE, Nguyen TM, Valabregue R, Henry PG, et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn Reson Med. 2015;73:1718–25.

14. Schmitz-Hubsch T, duMontcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.

15. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19:136–43.

16. Genis D, Matilla T, Volpini V, Rosell J, Davalos A, Ferrer I, et al. Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology. 1995;45:24–30.

17. Robitaille Y, Schut L, Kish SJ. Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA1) mutation define a unique phenotype. Acta Neuropathol. 1995;90:572–81.

18. Ratai EM, Gilberto GR. Clinical magnetic resonance spectroscopy of the central nervous system. Handb Clin Neurol. 2016;135:93–116.

19. Emir UE, Brent Clark H, Vollmers ML, Eberly LE, Oz G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem. 2013;127:660–8.

20. Mascalchi M, Tosetti M, Plasmati R, Bianchi MC, Tessa C, Salvi F, et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. J Neurol. 2015;262:1927–35.

21. Oz G, Nelson CD, Koski DM, Henry PG, Marjanska M, Deelchand DK, et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann Neurol. 2018;83:816–29.

22. Ratai EM, Gilberto GR. Clinical magnetic resonance spectroscopy of the central nervous system. Handb Clin Neurol. 2016;135:93–116.

23. Emir UE, Brent Clark H, Vollmers ML, Eberly LE, Oz G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem. 2013;127:660–8.

24. Wang PS, Liu RS, Yang BH, Soong BW. Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3
and 6: a voxel-based FDG-positron emission tomography analysis. J Neurol. 2007;254:838–45.
25. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinstein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47:215–22.
26. Tondo G, Iacarino L, Caminiti SP, Presotto L, Santangelo R, Iannaccone S, et al. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease. Alzheimers Res Ther. 2020;12:50.
27. Endo H, Sekiguchi K, Ueda T, Kowa H, Kanda F, Toda T. Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: a fluoro-deoxyglucose positron emission tomography study. eNeurologicalSci. 2017;6:74–9.
28. Firbank MJ, Yamall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88:310–6.
29. Lund TM, Risa O, Sonnewald U, Schousboe A, Waagepetersen HS. Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. J Neurochem. 2009;110:80–91.
30. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39:1–36.
31. Cvetanovic M. Decreased expression of glutamate transporter GLAST in Bergmann glia is associated with the loss of Purkinje neurons in the spinocerebellar ataxia type 1. Cerebellum. 2015;14:8–11.
32. Adanyeguh IM, Henry PG, Nguyen TM, Rinaldi D, Jauffret C, Valabregue R, et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord. 2015;30:662–70.
33. Valenzuela MJ, Jones M, Wen W, Rae C, Graham S, Shnier R, et al. Memory training alters hippocampal neurochemistry in healthy elderly. Neuroreport. 2003;14:1333–7.
34. Sanchez I, Balague E, Matilla-Duenas A. Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3beta-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1). Hum Mol Genet. 2016;25:4021–40.
35. Stucki DM, Ruegsegger C, Steiner S, Radecke J, Murphy MP, Zuber B, et al. Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ. Free Radic Biol Med. 2016;97:427–40.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations
Anne Sophie Grosch1 · Jan Leo Rinnenthal2,3,4 · Maria Rönnefarth1,5 · Silke Lux6 · Michael Scheel4,7 · Matthias Endres1,4,8,9 · Alexander U. Brandt10,11 · Friedemann Paul1,3,4 · Tanja Schmitz-Hübsch3,4 · Martina Minnerop12,13 · Sarah Doss1,14
1 Department of Neurology, Charité University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany
2 Department of Pathology, SANA Klinikum Offenbach, Offenbach, Germany
3 Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité University Medicine Berlin, Berlin, Germany
4 NeuroCure Clinical Research Center, Charité University Medicine Berlin, Berlin, Germany
5 Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany
6 Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany
7 Department of Neuroradiology, Charité University Medicine Berlin, Berlin, Germany
8 Center for Stroke Research Berlin (CSB), Charité University Medicine Berlin, Berlin, Germany
9 German Center of Neurodegenerative Diseases (DZNE), Berlin, Germany
10 German Centre for Cardiovascular Research (DZHK), Berlin, Germany
11 Department of Neurology, University of California, Irvine, CA, USA
12 Institute of Neuroscience and Medicine (INM-1), Research Centre Juelich, Juelich, Germany
13 Medical Faculty, Department of Neurology and Institute of Clinical Neuroscience and Medical Psychology, Center for Movement Disorders and Neuromodulation, Heinrich-Heine University, Düsseldorf, Germany
14 Movement Disorders Section, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA